Latest Balance Sheet News

ARC Funds Limited has secured $600,000 through a share placement priced at a 33% premium to its last traded price, aiming to strengthen its working capital and support growth initiatives.

Greatland Resources has locked in a $500 million debt facility with major banks, boosting liquidity to over $1.7 billion as it commits to developing its Havieron gold-copper project.

Lendlease is advancing its capital recycling strategy by selling the development rights to its Milano Santa Giulia North project in Milan for approximately $250 million, anticipating a significant operating loss in FY26.

BluGlass has locked in a $1 million firm commitment through an option shortfall agreement, with potential to raise $1.5 million, reinforcing its financial position after an upsized $8 million placement. The funds will accelerate GaN laser contract delivery and working capital.

Trek Metals has marked a breakthrough year with a high-grade manganese discovery at its Christmas Creek Project in Western Australia, supported by strong assay results and expanded exploration tenure. The company bolstered its balance sheet with $19.5 million raised to fund drilling and further exploration.

Carnarvon Energy has locked in the Transocean Equinox rig for a pivotal 2027 drilling campaign targeting major prospects in the Bedout Sub-basin, with costs comfortably covered by its strong cash reserves.

Findi Limited surged revenue by 36% to $83 million for FY26 but posted a hefty $52.6 million net loss, weighed down by integration costs and capital delays. The company completed a major consolidation of its Indian financial infrastructure assets and secured $25 million in fresh capital to support growth and liquidity.

Third Age Health Services posted a 17.9% revenue increase and 24.7% profit rise for FY26, driven by strategic acquisitions and expansion in aged residential care services.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Excite Technology Services lifted revenue by 74% to $21.3 million in FY26 but still recorded a $5.4 million loss, with auditors flagging material uncertainty over its ability to continue as a going concern.

New Talisman Gold Mines boosted revenue by 121% to NZ$53,000 but posted a $2.26 million net loss as it commissioned a processing plant and secured key commercial agreements.

Elanor Investors Group has called off its planned acquisition of Singapore-based Firmus Capital due to prolonged regulatory delays, while reaffirming its $125 million recapitalisation with Rockworth Capital Partners and seeking ASX trading reinstatement.